Avelumab in locally advanced or metastatic urothelial carcinoma.

Francesca Jackson-SpenceBernadett SzabadosCharlotte TomsYu-Hsuen YangChristopher SngThomas Powles

Published in: Expert review of anticancer therapy (2022)

Immune checkpoint inhibitor treatment in metastatic UC holds much promise, but has not been optimized. First-line maintenance avelumab is an attractive option for these patients. Future research will significantly change the landscape of treatment in the near future.

Keyphrases

squamous cell carcinoma
small cell lung cancer
locally advanced
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
radiation therapy
machine learning
combination therapy
single cell
big data
artificial intelligence
lymph node
patient reported outcomes